Urinary tract physiological conditions promote ciprofloxacin resistance in low-level-quinolone-resistant Escherichia coli by Martín Gutiérrez, Guillermo et al.
Urinary Tract Physiological Conditions Promote Ciprofloxacin
Resistance in Low-Level-Quinolone-Resistant Escherichia coli
Guillermo Martín-Gutiérrez,a,c Jerónimo Rodríguez-Beltrán,a José Manuel Rodríguez-Martínez,b Coloma Costas,a Javier Aznar,a,c
Álvaro Pascual,b,c Jesús Blázqueza,d
Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Seville, Spaina; Departamento de Microbiología, Universidad
de Sevilla, Seville, Spainb; Unidad Intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del
Rocío, Seville, Spainc; Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spaind
Escherichia coli isolates carrying chromosomally encoded low-level-quinolone-resistant (LLQR) determinants are frequently
found in urinary tract infections (UTIs). LLQR mutations are considered the first step in the evolutionary pathway producing
high-level fluoroquinolone resistance. Therefore, their evolution and dissemination might influence the outcome of fluoroquin-
olone treatments of UTI. Previous studies support the notion that low urine pH decreases susceptibility to ciprofloxacin (CIP) in
E. coli. However, the effect of the urinary tract physiological parameters on the activity of ciprofloxacin against LLQR E. coli
strains has received little attention. We have studied the activity of ciprofloxacin under physiological urinary tract conditions
against a set of well-characterized isogenic E. coli derivatives carrying the most prevalent chromosomal mutations (marR,
gyrA-S83L, gyrA-D87N, and parC-S80R and some combinations). The results presented here demonstrate that all the LLQR
strains studied became resistant to ciprofloxacin (according to CLSI guidelines) under physiological conditions whereas the con-
trol strain lacking LLQR mutations did not. Moreover, the survival of some LLQR E. coli variants increased up to 100-fold after
challenge with a high concentration of ciprofloxacin under UTI conditions compared to the results seen with Mueller-Hinton
broth. These selective conditions could explain the high prevalence of LLQR mutations in E. coli. Furthermore, our data strongly
suggest that recommended methods for MIC determination produce poor estimations of CIP activity against LLQR E. coli in
UTIs.
Ciprofloxacin (CIP) is one of the agents commonly utilized fortreatment of urinary tract infections (UTIs) (1–3). It is used as
an appropriate therapy in patients with UTI not requiring hospi-
talization in areas where the prevalence of resistance is under 10%.
In addition, it is considered an effective treatment in the preven-
tion of UTI in kidney transplant recipients (4, 5). However, during
recent years a clear increase in resistance to fluoroquinolones
(FQ) has been described worldwide (6, 7).
The predominant causative agent of community-acquired
UTI, Escherichia coli, acquires resistance mainly through chromo-
somal mutations in the genes encoding subunits of the DNA gy-
rase (gyrA and gyrB genes) and topoisomerase IV (parC and parE
genes) or in regulatory genes affecting permeability or efflux (8).
Some of these mutations lead to generation of low-level-quinolo-
ne-resistant (LLQR) E. coli mutants, with a CIP MIC that is higher
than the epidemiological cutoff value but still below the resistance
breakpoint for most FQs. A high (from 17% to 39%, depending on
the study) prevalence of LLQR E. coli in UTIs has been previously
described (8, 9). However, the causes of this prevalence are un-
clear, as the high CIP levels found in the bladder after treatment
should be sufficient to eradicate any susceptible bacteria.
It has been stated that small increases in MIC values produced
by LLQR mutations have a profound impact on the mutant, pre-
venting concentration of FQs and raising the likelihood that
strains with high-level resistance will appear (10). Therefore,
LLQR mutants are arguably the first step on the evolutionary
pathway to producing high-level quinolone resistance, and thus
their dissemination and evolution might influence the outcome of
FQ treatment of UTI.
One of the determinants of this outcome is the environment
found in the urinary tract, which is characterized mainly by the
presence of urine and anaerobic conditions. Urine is a fluctuating
and complex fluid composed of over 95% water, plus sodium,
ammonia, phosphate, sulfate, urea, creatinine, proteins, and
products processed by the kidney and liver (11). The variability in
the physicochemical properties of urine is best illustrated by the
wide pH range of human urine, which normally varies from 5 to 8
(12). Additionally, the bladder environment is mainly anaerobic,
with a concentration of dissolved oxygen (DO) in urine of about
4.2 ppm (13); the concentration is also variable and mainly reflects
the renal metabolic state. Moreover, in patients with urinary in-
fections, the urine DO concentration is significantly reduced as a
result of oxygen consumption by the infecting microbes (13).
However, the relative contributions of these parameters to the
possible outcomes of CIP treatment against LLQR strains have
received little attention. CIP is an ampholyte consisting of an
acidic group and a basic group that can exist in four different
pH-dependent protonation forms (14). The zwitterionic form is
necessary for bacterial permeability, while the neutral form pro-
vides good intestinal absorption (15). Therefore, the wide range of
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pH found in human urine can affect the ionization status of CIP
and can thus modify its antimicrobial activity (16–19). Regarding
oxygen levels, it has been reported that growth under conditions
of anaerobiosis affects bacterial susceptibility to CIP (20). There-
fore, both parameters could, in principle, influence the resistance
profiles of LLQR UTI strains, thus affecting the prognosis of treat-
ment.
Pharmacokinetic and pharmacodynamic (PK/PD) studies in-
dicate that very high (up to 990 g/ml) concentrations of CIP can
be reached in urine during treatment (21), suggesting that, despite
a possible effect of pH and other urine parameters on CIP activity,
such treatment should be sufficient to kill any susceptible bacteria.
However, to date, no studies on the effect of these parameters on
the activity of CIP against strains containing LLQR mutations
have been performed.
Consequently, we aimed to evaluate the impact of the above-
mentioned parameters (namely, growth in urine, pH, and anaer-
obiosis) on the antimicrobial activity of CIP against a set of well-
characterized isogenic LLQR strains carrying the most frequent
chromosomal mutations (9, 22) and against a series of E. coli clin-
ical isolates with known LLQR mutations. MICs of CIP in both
Mueller-Hinton broth (MH) and urine under various pH and
oxygen supply conditions were studied. In addition, the survival
rates of these strains in the presence of the maximum concentra-
tion of CIP reached in the bladder were also analyzed.
MATERIALS AND METHODS
Strains and growth conditions. Wild-type E. coli ATCC 25922 and nine
different isogenic strains carrying combinations of the most prevalent
chromosomal mutations (marR, gyrA-S83L, gyrA-D87N, and parC-
S80R) were used. Isogenic strains were those constructed previously by
Machuca et al. (23). Moreover, six uropathogenic E. coli (UPEC) strains
with well-characterized LLQR mutations that had been isolated from pa-
tients in the University Hospital Marques de Valdecilla and University
Hospital Virgen Macarena during 2009 were studied (Table 1).
MH (Conda Pronadisa, Spain) was used as a control medium. For
growth rate determinations, overnight cultures of the strains were diluted
1:100 into MH and cultured with aeration at 37°C during 2 h at 180 rpm
to obtain bacteria in the exponential-growth phase. Growth assays were
conducted in clear flat-bottom 96-well MicroWell plates (Nunc, Roskilde,
Denmark), containing 8 replicates of 100 l per sample. The plates were
incubated at 37°C with shaking on an automated microplate reader (In-
finite M200; Tecan, Männedorf, Switzerland), and the absorbance at 595
nm for each well was measured every 30 min. The duration of each assay
was 24 h.
Urine obtained from 3 healthy volunteers who had not received anti-
biotic treatment during the previous 6 months was pooled, sterilized by
filtration through 0.22-mm-pore-size filters (polyethersulfone [PES]
membrane) (VWR, United Kingdom), divided into aliquots, and stored
at 20°C. The urine was adjusted to pH values of 5.0, 6.0, and 7.0 with
HCl or NaOH (both from Sigma-Aldrich), and the samples were again
subjected to sterile filtration before use. Urine-agar plates were made by
mixing 4:1 pH-adjusted pooled human urine with 6% agar (Conda Pro-
nadisa, Spain). Final pH values were determined for urine-agar before
plating and were readjusted when necessary.
Measurement of pH of urine from patients with community-ac-
quired E. coli UTI. From March 2015 to June 2015, 18-year-old patients
with UTI symptoms receiving care at the Primary Care Units of Virgen del
Rocío University Hospital were included in this study. Midstream catch
urine was collected in sterile preservative tubes (SRO-1-25B; Soria Mel-
guizo S.A., Madrid, Spain) and was transported on ice. Urine samples
were processed within 4 to 8 h after collection. For each sample, 10 l of
urine was quantitatively cultured onto Brilliance UTI Clarity agar plates
(Oxoid, Basingstoke, United Kingdom). All plates were aerobically incu-
bated for 18 to 24 h at 37°C, and the results were expressed as the number
of CFU per milliliter. Urine pH was measured in each collected specimen
with a pH meter.
Cultures in which E. coli levels were above thresholds of 105 CFU/ml
for women and 103 CFU/ml for men were defined as positive. In total,
pH values of urine from 136 patients (with proven UTI caused by E. coli)
were included.
Susceptibility testing. MICs of CIP were determined in triplicate for
each bacterial strain using the broth microdilution method, according to
the Clinical and Laboratory Standards Institute (CLSI) reference methods
(24). Overnight cultures were prepared and adjusted to a density of 0.5
McFarland. To reproduce urine physiological conditions, the MICs of
CIP were measured in MH and urine at pH values of 5, 6, and 7. To
determine if the effect was due only to the decrease in pH, MICs were also
measured in MH at pH 5 and pH 6, in addition to the standard pH of MH
broth (7.3  0.1). Microplates were incubated under aerobic and anaer-
obic conditions.
MICs of CIP were also determined by a gradient MIC strip methodol-
ogy (Liofilchem srl, Italy) according to CLSI criteria. Bacterial suspen-
sions were prepared from overnight cultures and adjusted to a density of
0.5 McFarland. Gradient MIC strip experiments were performed on MH
agar (Difco, Soria Melguizo, Spain) and urine-agar with pH values of 5, 6,
and 7. Plates were incubated under aerobic conditions for 24 h (48 h for
urine-agar tests) at 37°C.
Survival rates. Overnight cultures of the different strains were grown
at 37°C without the antimicrobial agent in both MH and urine at different
pH values. Then, bacteria at a density of 5  105 CFU/ml from these
cultures were inoculated into fresh MH or urine containing CIP and were
incubated at 37°C for 6 h in anaerobiosis. The quinolone concentration
used for determination of survival rates was 1,000 g/ml, slightly above
the maximum concentration of CIP reached in urine within the first 6 h
after administration of an oral dose of 500 mg CIP (21), which is the
recommended dose for adults (4). Antibiotic-free broth was evaluated in
parallel as a control. Viable counts were determined by plating serial di-
lutions onto MH agar plates incubated at 37°C for up to 24 h. The survival
rate was calculated by normalizing the number of surviving bacteria to the
estimated initial population.
TABLE 1 Genotypes of isogenic and UPEC strainsa
Strain
Genotype







EC05 S83L S80R 
EC06 S83L D87N
EC07 S83L D87N 
EC08 S83L D87N S80R








a UPEC, uropathogenic Escherichia coli strains; , precise deletion.
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Variability of pH in urine from UTI patients. We first conducted
a prospective study to measure the urine pH from patients with
community-acquired E. coli UTI. The results presented in Fig. 1
demonstrate a wide variability in pH values, ranging from 5 to 8,
suggesting that physiological urinary pH is highly variable among
patients. We found that the vast majority (90%) of pH values were
below neutrality, with most samples being markedly acidic (63%
with pH  6). This result, which agrees with a previous report
(25), indicates that low urine pH is the rule rather than the excep-
tion in UTI patients.
Effect of urine pH on the growth of E. coli ATCC 25922. We
then studied the ability of the E. coli ATCC 25922 strain to grow in
urine at physiological pH values. Growth curves in MH and urine
were carried out using an automated spectrophotometer under
controlled conditions of temperature and shaking. Figure 2 shows
that E. coli ATCC 25922 was able to prosper in urine, although its
growth was somewhat lower than that in MH, probably due to the
low concentration of nutrients. Acidification of urine, including
pH 5, led to only small decreases in growth, demonstrating that E.
coli is well adapted to extreme pH values. Similarly, all LLQR de-
rivatives were able to grow in urine at different pH values (data not
shown). It should be noted here that we were unable to perform
growth curve determinations in basic urine (pH 8) because, under
our conditions, urine components precipitate at pH values higher
than 7. This, together with the fact that basic urine is uncommon
among UTI patients (	5%) (Fig. 1), led us to exclude this condi-
tion from further experiments.
Effect of pH and anaerobiosis on the activity of CIP against
LLQR E. coli strains growing in urine. To determine if CIP activ-
ity is affected by urine acidification, we performed preliminary
MIC determinations using of a combination of the gradient MIC
strip methodology and pH-adjusted urine agar plates (see Mate-
rials and Methods). As expected, pH values had a large influence
on the CIP MICs detected by gradient MIC strips for all LLQR
strains. Figure 3 shows an illustrative example with ATCC 25922
and its gyrA-S83L–parC-S80R derivative EC05.
The activity of CIP against all LLQR isogenic derivatives was
also determined in urine under different conditions (pH and an-
aerobiosis) by the microdilution method. Table 2 confirms that
pH had a large influence on MICs, with 4-fold to 16-fold MIC
increases in the ATCC 25922 strain and its isogenic LLQR deriv-
atives when the pH was changed from neutral to 6. Importantly,
with the exception of the ATCC 25922 and EC01 (marR) strains,
all susceptible strains became resistant (MIC of 
4 g/ml) ac-
cording to CLSI classification. The MIC increases were even
higher when the urine pH was set to 5. Under those conditions,
CIP activity decreased 32-fold to 256-fold in comparison to the
activity seen at pH 7. At pH 5, all strains except ATCC 25922 were
resistant to CIP, as defined by CLSI guidelines. Taken together,
these results indicate that the presence of any of the studied LLQR
mutations was enough to confer clinical levels of resistance at
acidic but physiological pH. Remarkably, the ATCC 25922 strain,
which lacks any of these resistance determinants, remained sus-
ceptible under these conditions.
Regarding the effect of anaerobiosis, Table 2 (nO2 columns)
shows that growth under anaerobic conditions increased the CIP
MICs 2-fold to 8-fold at pH 7 compared to the values obtained
FIG 1 Distribution of urine pH values in 136 samples from patients with UTI
caused by E. coli.
FIG 2 Growth curves of E. coli ATCC 25922 growing in MH and urine at
different pH values. Error bars represent standard errors of the means of re-
sults from at least four replicates. MH, Mueller-Hinton; UR, urine; OD, optical
density.
FIG 3 CIP susceptibility testing for two representative strains (ATCC 25922
and EC05), using the gradient MIC strip methodology. It was observed that pH
has a great influence on CIP activity, with a significant increase in MICs when
pH decreases. MICs (shown in micrograms per milliliter) are indicated at the
right bottom for each condition. UR 7, urine-agar pH 7; UR 6, urine-agar pH
6; UR 5, urine-agar pH 5.
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with oxygen, converting all strains, except ATCC 25922 and EC01,
to intermediate or resistant. The increases due to the absence of
oxygen at pH 6 were minimal (from 2-fold to 4-fold), and there
were almost no changes at pH 5.
In summary, these results demonstrate that the pH of urine
had a great effect on the activity of CIP against the E. coli ATCC
25922 LLQR isogenic derivatives, with a pH of 5 capable of con-
verting all LLQR strains to intermediate or resistant to CIP ac-
cording to CLSI breakpoints. Furthermore, growth in urine at
neutral pH under anaerobic conditions produced an increase in
MIC values sufficient for classifying eight strains as resistant which
would have been considered susceptible by traditional MIC deter-
minations in MH.
Table 3 shows that, similarly to the results obtained with urine,
acidification of MH had a great effect on CIP activity, with in-
creases of 8-fold to 16-fold and 32-fold to 64-fold at pH 6 and 5,
respectively. At pH 6, all strains, except ATCC 25922 and EC01,
became resistant or intermediate, as defined by the CLSI clinical
breakpoints. On the other hand, growth in the absence of oxygen
had a smaller effect in MH than in urine, with CIP activity in-
creases of 2-fold to 4-fold at pH 7 and almost no effect at pH 6 and
5. Therefore, growth in urine exacerbated the effect of pH and
anaerobiosis on the CIP activity with respect to growth in MH.
MIC determinations under physiological conditions. Cur-
rent methods employed to determine MICs in clinical microbiol-
ogy laboratories are based on growth in MH broth or on MH agar
plates in which the pH is close to neutrality (standard pH is 7.3 
0.1). Therefore, according to the results described above, when
CIP reaches the bladder, the environmental conditions could alter
its antimicrobial activity. Table 4 shows the fold change in MICs
when the strains are grown in urine at different pH and oxygen
levels in comparison to those obtained using classical MIC deter-
mination methods (MH broth, pH 7.3, and aerobiosis). These
results indicate that anaerobic growth in urine increased the CIP
MIC at pH 7 (2-fold to 8-fold), pH 6 (16-fold to 64-fold), and pH
5 (128-fold to 512-fold).
Survival rates at the maximum physiological CIP concentra-
tion. The results presented above suggest that CIP treatment of
LLQR strains could be inefficient under UTI physiological condi-
tions. To test this possibility, overnight cultures of the different
strains were grown at 37°C without the antimicrobial agent in
both MH and urine at different pH values. Then, bacteria at a
density of about 5  105 CFU/ml were inoculated into fresh MH
or urine containing CIP (1,000 g/ml) and grown at 37°C during
6 h. The rationale for this experimental design was to mimic the
best-case scenario, using the addition of the highest CIP concen-
tration ever reported within the first 6 h after an oral dose of 500
TABLE 5 Ciprofloxacin MICs against clinical strains in MH broth and
urine at different pH valuesa
Strain
MIC (g/ml)
MH broth Urine pH 7 Urine pH 6 Urine pH 5
O2 nO2 O2 nO2 O2 nO2 O2 nO2
Val09 1 2 1 8 8 16 256 256
MAC02 0.125 0.25 0.25 0.5 1 1 32 16
MAC10 0.25 0.5 0.125 0.5 1 4 32 16
MAC11 0.5 2 0.25 2 2 4 64 64
MAC21a 0.5 2 0.25 2 2 4 64 64
MAC33 0.125 0.5 0.25 0.25 0.5 1 8 8
a Intermediate and resistant MIC values according to the CLSI guideline are shown in
bold. O2, aerobic incubation; nO2, anaerobic incubation.




UR pH 7 UR pH 6 UR pH 5
O2 nO2 O2 nO2 O2 nO2
ATCC 25922 0.015 0.03 0.06 0.25 1 1
EC01 0.03 0.06 0.25 0.5 4 2
EC02 0.25 1 4 4 32 32
EC03 0.5 2 8 16 64 32
EC04 0.5 2 8 16 64 64
EC05 1 4 16 64 256 256
EC06 1 1 4 4 32 32
EC07 0.5 2 8 16 64 64
EC08 4 8 32 64 512 512
EC09 8 16 64 256 512 512
a Intermediate and resistant MIC values according to the CLSI guideline are shown in
bold. O2, aerobic incubation; nO2, anaerobic incubation.
TABLE 3 MICs of ciprofloxacin for isogenic E. coli strains in MH broth
at different pH valuesa
Strain
MIC (g/ml) in MH broth at pH:
7 6 5
O2 nO2 O2 nO2 O2 nO2
ATCC 25922 0.004 0.008 0.03 0.06 0.125 0.125
EC01 0.008 0.06 0.125 0.125 0.5 0.25
EC02 0.125 0.25 1 1 4 4
EC03 0.25 1 2 4 8 8
EC04 0.5 1 4 4 16 16
EC05 1 4 8 8 64 32
EC06 0.125 0.25 1 1 4 4
EC07 0.25 1 4 4 16 16
EC08 2 4 16 16 64 128
EC09 4 16 32 64 256 128
a Intermediate and resistant MIC values according to the CLSI guideline are shown in
bold. O2, aerobic incubation; nO2, anaerobic incubation.
TABLE 4 Mean fold changes in MICs of ciprofloxacin in MH broth and
urine at different values of pH and anaerobiosisa
Strain
MIC (g/ml) in MH broth and urine at pH:
7 6 5
O2 nO2 O2 nO2 O2 nO2
ATCC 25922 4 8 32 64 128 256
EC01 1 8 8 64 32 256
EC02 4 8 16 32 128 256
EC03 2 8 16 64 32 128
EC04 2 4 16 32 64 128
EC05 1 4 16 64 64 256
EC06 4 8 16 32 128 256
EC07 2 8 16 64 64 256
EC08 2 4 16 32 128 256
EC09 1 4 16 64 32 128
a O2, aerobic incubation; nO2, anaerobic incubation.
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mg, although the concentration that CIP reaches in the bladder is
typically lower (21). Note that we decided to use such a high con-
centration because we anticipated that the median CIP concentra-
tion during the first hours of treatment (268 g/ml) (21) would be
in a range near or below the MIC for several LLQR strains in urine
under conditions of low pH (see Table 2); hence, the effects of CIP
treatment against these strains would most likely be innocuous.
Figure 4 shows that the survival rates of all strains, except ATCC
25922 and EC01, whose survival rates fall below the detection limit
of our assay, increased substantially (10-fold to 100-fold) in urine
at pH 5 compared with those seen with MH. At higher pH values,
no statistically significant differences in survival were found, ex-
cept for EC02.
Effect of urine, pH, and anaerobiosis on CIP activity against
LLQR clinical isolates. To discard the possibility that the ob-
served effects were specific to the E. coli ATCC 25922 strain and its
derivatives, we scored the MICs of CIP against six well-character-
ized LLQR E. coli clinical strains. As for the ATCC 25922 strain, the
MIC showed a marked increase when determinations were per-
formed in urine at different pHs and under anaerobic conditions.
In this case, three of six strains became intermediate, as defined by
the CLSI breakpoints, when MIC determinations were performed
in urine at pH 7 under conditions of anaerobiosis. Further in-
creases were displayed in urine with acidic pHs; all clinical strains
demonstrated resistance at pH 5 (Table 5).
DISCUSSION
The effectiveness of CIP for the treatment of UTI does not depend
on pathogen susceptibility alone. Physicochemical and pharma-
cological properties of antibiotics are important factors related to
successful therapy. Because CIP is an ampholyte (14), the pH of
urine affects its ionization status, which is critical for its activity
and cellular accumulation in both bacteria and bladder cells. Re-
sults of previous studies support the notion that low urine pH
decreases susceptibility to CIP in a number of bacterial pathogens
(16–19, 25).
Our results confirm that growth in urine at neutral pH slightly
increases resistance to CIP in E. coli (26). This increase is further
enhanced in an anaerobic environment, such as that found in the
bladder. Importantly, growth in acidic urine renders all LLQR
strains resistant to CIP according to CLSI breakpoints. These re-
sults suggest that traditional susceptibility testing in MH broth
may result in poor estimations of CIP activity in UTI caused by
LLQR strains.
It has been suggested that the high concentrations of FQ at-
tained in the urinary tract are enough to eradicate bacterial patho-
gens, even those which, following CLSI guidelines, would have
been considered resistant (27). This assumption is made based on
the empirical success of treatments with CIP against resistant
clones and the predictive values of PK/PD modeling for FQ effec-
tiveness, which, given the high values of maximum concentration
of drug in serum (Cmax) and area under the concentration-time
curve (AUC) reached in the urinary tract, predict the clinical re-
sponse for strains with drug MIC values as high as 20 g/ml
(28). According to our results, the application of this criterion to
MIC data for LLQR strains suggests that growth in human urine,
under physiological conditions of pH and oxygen concentration,
could cause treatment failure in most cases. Similar behavior is
expected for other fluoroquinolones; for instance, the activity of
levofloxacin, moxifloxacin, and ofloxacin is also affected by
growth in urine, pH, and anaerobiosis (29, 30).
To further validate this prediction, we developed a survival
assay in which bacteria were exposed to an extremely high con-
centration of CIP (approximately 4-fold the median concentra-
tion in urine) within the first 6 h (21) in urine adjusted to different
pH values and in anaerobiosis. Our results show that, especially
under acidic conditions, survival is enhanced 10-fold to 100-fold
in most strains compared to the rate seen with MH at neutral pH.
Furthermore, most LLQR strains showed a relatively small (1 to 2
log) decrease in viability, despite the high CIP concentration that
was used. In contrast, the strain lacking any FQ resistance deter-
minant (ATCC 25922) was unable to cope with the simulated CIP
treatment, highlighting the importance of LLQR mutations in
treatment failure. Once again, these results raise issues regarding
FIG 4 Survival rates of E. coli isogenic strains treated with 1,000 g/ml of CIP after 6 h under anaerobic conditions. Survival rates were calculated by dividing the
number of CFU per milliliter after CIP incubation by the value obtained at time zero. All results were obtained by at least three independent experiments. Error
bars represent standard deviations. Asterisks denote statistically significant differences (P 	 0.05 [Student=s t test]) between conditions in comparison to the
respective survival rate in Mueller-Hinton for every strain.
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the clinical success of CIP against LLQR strains under physiolog-
ical conditions and should be interpreted as cautionary.
Despite the general belief that multiple mutations are required
to generate clinically important resistance in E. coli (31), the re-
sults presented here show that UTIs could produce ideal condi-
tions for the generation and selection of single LLQR mutants.
Furthermore, the high survival rates that we found upon CIP ex-
posure could be a determining factor in the development of mul-
tistep resistance mutants. FQs have been demonstrated to act as
mutagens and to have a stimulatory effect on recombination fre-
quency (32, 33), accelerating bacterial evolution and antibiotic
resistance. It is conceivable, therefore, that in urine at low pH,
prevalent mutations conferring LLQR such as GyrA S83L could
provide the basal level of resistance needed to withstand the first
hours of treatment. This may provide a window for the emergence
of further resistance fueled by the mutagenic effect of CIP. In
agreement, it has been reported that patients previously treated
with FQ are prone to urinary tract infection caused by CIP-resis-
tant E. coli (34). In summary, urinary tract conditions may repre-
sent an environment in which LLQR mutants would be selected
under conditions of treatment with CIP (and possibly other FQs).
This could explain, at least partially, the high prevalence of these
mutations and raises concerns about the appropriateness of CIP
treatments when LLQR strains are detected.
Concerning the clinical and physiological characteristics of pa-
tients with UTI caused by E. coli, there are several factors that
should be taken into consideration when CIP is employed. It has
been reported that the composition of the diet affects the acid-
base balance in the body. A higher protein intake significantly
increases renal acid excretion by increasing ammonium output,
thus acidifying the urine (35, 36). Moreover, the effect of urine pH
on CIP activity may become relevant in patients with certain un-
derlying diseases. Thus, it is known that patients with hyperten-
sion are associated with a lower urinary citrate level and a higher
level of acid excretion, resulting in lower urine pH values (37).
This effect can also be found in patients with type 2 diabetes or
metabolic acidosis (38, 39). There are some patient characteristics
that are related to lower pH values in urine, such as older age or
higher body weight (38, 40, 41). Some medications, such as loop
diuretics or mineralocorticoids, can also acidify urine (42, 43).
Therefore, treatment with CIP for UTI in patients with factors
related to urine acidification could result in therapeutic failure
and increased selective pressure, promoting the development of
bacterial resistance. Thus, urinary pH values could have practical
interest in the management of these patients, where the physician
should select the course best suited to the individual patient: either
basifying the urine by alkalinization (e.g., by the use of potassium
citrate or sodium bicarbonate) (44, 45) with the aim of increasing
the activity of CIP or electing to use other antibiotics not affected
by low pH values.
ACKNOWLEDGMENT
We are grateful to Michael McConnell for useful scientific comments and
English revision of the manuscript.
FUNDING INFORMATION
This work was supported by the Subdirección General de Redes y Centros
de Investigación Cooperativa, Ministerio de Economía y Competitividad,
Instituto de Salud Carlos III, Spanish Network for Research in Infectious
Diseases (grant RD12/0015/0012; REIPI RD12/0015/0012), cofinanced by
European Development Regional Fund A way to achieve Europe ERDF,
and Fondo de Investigación Sanitaria (grant PI13/00063).
REFERENCES
1. van der Starre WE, van Nieuwkoop C, Paltansing S, van’t Wout JW,
Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM,
Ablij HC, Leyten EMS, Blom JW, van Dissel JT. 2011. Risk factors for
fluoroquinolone-resistant Escherichia coli in adults with community-
onset febrile urinary tract infection. J Antimicrob Chemother 66:650 –
656. http://dx.doi.org/10.1093/jac/dkq465.
2. Etienne M, Lefebvre E, Frebourg N, Hamel H, Pestel-Caron M, Caron
F, Bacyst Study Group. 2014. Antibiotic treatment of acute uncompli-
cated cystitis based on rapid urine test and local epidemiology: lessons
from a primary care series. BMC Infect Dis 14:137. http://dx.doi.org/10
.1186/1471-2334-14-137.
3. van den Broek d’Obrenan J, Verheij TJ, Numans ME, van der Velden
AW. 2014. Antibiotic use in Dutch primary care: relation between diag-
nosis, consultation and treatment. J Antimicrob Chemother 69:1701–
1707. http://dx.doi.org/10.1093/jac/dku005.
4. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran
GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases
Society of America; European Society for Microbiology and Infectious
Diseases. 2011. International clinical practice guidelines for the treatment
of acute uncomplicated cystitis and pyelonephritis in women: a 2010 up-
date by the Infectious Diseases Society of America and the European So-
ciety for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–
e120. http://dx.doi.org/10.1093/cid/ciq257.
5. Parasuraman R, Julian K; AST Infectious Diseases Community of
Practice. 2013. Urinary tract infections in solid organ transplantation. Am
J Transplant 13(Suppl 4):S327–S336. http://dx.doi.org/10.1111/ajt.12124.
6. Aypak C, Altunsoy A, Düzgün N. 2009. Empiric antibiotic therapy in
acute uncomplicated urinary tract infections and fluoroquinolone resis-
tance: a prospective observational study. Ann Clin Microbiol Antimicrob
8:27. http://dx.doi.org/10.1186/1476-0711-8-27.
7. Lautenbach E, Strom BL, Nachamkin I, Bilker WB, Marr AM, Larosa
LA, Fishman NO. 2004. Longitudinal trends in fluoroquinolone resis-
tance among Enterobacteriaceae isolates from inpatients and outpatients,
1989 –2000: differences in the emergence and epidemiology of resistance
across organisms. Clin Infect Dis 38:655– 662. http://dx.doi.org/10.1086
/381549.
8. Takahashi A, Muratani T, Yasuda M, Takahashi S, Monden K, Ishikawa
K, Kiyota H, Arakawa S, Matsumoto T, Shima H, Kurazono H,
Yamamoto S. 2009. Genetic profiles of fluoroquinolone-resistant Esche-
richia coli isolates obtained from patients with cystitis: phylogeny, viru-
lence factors, PAIusp subtypes, and mutation patterns. J Clin Microbiol
47:791–795. http://dx.doi.org/10.1128/JCM.01740-08.
9. Komp Lindgren P, Karlsson A, Hughes D. 2003. Mutation rate and
evolution of fluoroquinolone resistance in Escherichia coli isolates from
patients with urinary tract infections. Antimicrob Agents Chemother 47:
3222–3232. http://dx.doi.org/10.1128/AAC.47.10.3222-3232.2003.
10. Hooper DC, Jacoby GA. 17 July 2015. Mechanisms of drug resistance:
quinolone resistance. Ann N Y Acad Sci http://dx.doi.org/10.1111/nyas
.12830.
11. Marin SJ, Coles R, Merrell M, McMillin GA. 2008. Quantitation of
benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS.
J Anal Toxicol 32:491– 498. http://dx.doi.org/10.1093/jat/32.7.491.
12. Bilobrov VM, Chugaj AV, Bessarabov VI. 1990. Urine pH variation
dynamics in healthy individuals and stone formers. Urol Int 45:326 –331.
http://dx.doi.org/10.1159/000281730.
13. Giannakopoulos X, Evangelou A, Kalfakakou V, Grammeniatis E, Pa-
pandropoulos I, Charalambopoulos K. 1997. Human bladder urine ox-
ygen content: implications for urinary tract diseases. Int Urol Nephrol
29:393– 401. http://dx.doi.org/10.1007/BF02551103.
14. Völgyi G, Vizserálek G, Takács-Novák K, Avdeef A, Tam KY. 2012.
Predicting the exposure and antibacterial activity of fluoroquinolones
based on physicochemical properties. Eur J Pharm Sci 47:21–27. http://dx
.doi.org/10.1016/j.ejps.2012.04.022.
15. O’Shea R, Moser HE. 2008. Physicochemical properties of antibacterial
compounds: implications for drug discovery. J Med Chem 51:2871–2878.
http://dx.doi.org/10.1021/jm700967e.
16. Smith SM, Eng RH, Cherubin CE. 1988. Conditions affecting the results
LLQR E. coli Resistance in UTI
July 2016 Volume 60 Number 7 aac.asm.org 4257Antimicrobial Agents and Chemotherapy


























of susceptibility testing for the quinolone compounds. Chemotherapy 34:
308 –314. http://dx.doi.org/10.1159/000238584.
17. Zeiler HJ. 1985. Influence of pH and human urine on the antibacterial
activity of ciprofloxacin, norfloxacin and ofloxacin. Drugs Exp Clin Res
11:335–338.
18. Zhanel GG, Karlowsky JA, Davidson RJ, Hoban DJ. 1991. Influence of
human urine on the in vitro activity and postantibiotic effect of cipro-
floxacin against Escherichia coli. Chemotherapy 37:218 –223. http://dx
.doi.org/10.1159/000238857.
19. Aagaard J, Gasser T, Rhodes P, Madsen PO. 1991. MICs of ciprofloxacin
and trimethoprim for Escherichia coli: influence of pH, inoculum size and
various body fluids. Infection 19(Suppl 3):S167–S169.
20. Linde H-J, Lehn N. 2004. Mutant prevention concentration of nalidixic
acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin,
sparfloxacin or trovafloxacin for Escherichia coli under different growth
conditions. J Antimicrob Chemother 53:252–257. http://dx.doi.org/10
.1093/jac/dkh036.
21. Wagenlehner FME, Kinzig-Schippers M, Sörgel F, Weidner W, Naber
KG. 2006. Concentrations in plasma, urinary excretion and bactericidal
activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy
volunteers receiving a single oral dose. Int J Antimicrob Agents 28:551–
559. http://dx.doi.org/10.1016/j.ijantimicag.2006.07.026.
22. Hopkins KL, Davies RH, Threlfall EJ. 2005. Mechanisms of quinolone
resistance in Escherichia coli and Salmonella: recent developments. Int J
Antimicrob Agents 25:358 –373. http://dx.doi.org/10.1016/j.ijantimicag
.2005.02.006.
23. Machuca J, Briales A, Labrador G, Díaz-de-Alba P, López-Rojas R,
Docobo-Pérez F, Martínez-Martínez L, Rodríguez-Baño J, Pachón ME,
Pascual Á Rodríguez-Martínez J-M. 2014. Interplay between plasmid-
mediated and chromosomal-mediated fluoroquinolone resistance and
bacterial fitness in Escherichia coli. J Antimicrob Chemother 69:3203–
3215. http://dx.doi.org/10.1093/jac/dku308.
24. Clinical and Laboratory Standards Institute. 2015. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically; ap-
proved standard— 10th ed. CLSI document M07-A10. Clinical and Lab-
oratory Standards Institute, Wayne, PA.
25. So W, Crandon JL, Nicolau DP. 2015. Effects of urine matrix and pH on
the potency of delafloxacin and ciprofloxacin against urogenic Escherichia
coli and Klebsiella pneumoniae. J Urol 194:563–570. http://dx.doi.org/10
.1016/j.juro.2015.01.094.
26. Barry AL. 1990. In vitro activity of the quinolones and related compounds,
p 79 –105. In Siporin C, Heifetz CL, Domagala JM (ed), The new genera-
tion of quinolones. Marcel Dekker, New York, NY.
27. Miller LG, Mehrotra R, Tang AW. 2007. Does in vitro fluoroquinolone
resistance predict clinical failure in urinary tract infections? Int J Antimi-
crob Agents 29:605– 607. http://dx.doi.org/10.1016/j.ijantimicag.2006.11
.021.
28. Sánchez Navarro MD, Coloma Milano C, Zarzuelo Castañeda A, Say-
alero Marinero ML, Sánchez-Navarro A. 2002. Pharmacokinetics of
ciprofloxacin as a tool to optimise dosage schedules in community pa-
tients. Clin Pharmacokinet 41:1213–1220. http://dx.doi.org/10.2165
/00003088-200241140-00005.
29. Lewin CS, Morrissey I, Smith JT. 1991. The mode of action of quino-
lones: the paradox in activity of low and high concentrations and activity
in the anaerobic environment. Eur J Clin Microbiol Infect Dis 10:240 –
248. http://dx.doi.org/10.1007/BF01966996.
30. Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M. 2011. Impact of
pH on bacterial growth and activity of recent fluoroquinolones in pooled
urine. Res Microbiol 162:249 –252. http://dx.doi.org/10.1016/j.resmic
.2011.01.004.
31. Hooper DC. 2001. Emerging mechanisms of fluoroquinolone resistance.
Emerg Infect Dis 7:337–341. http://dx.doi.org/10.3201/eid0702.010239.
32. Gocke E. 1991. Mechanism of quinolone mutagenicity in bacteria. Mutat
Res 248:135–143. http://dx.doi.org/10.1016/0027-5107(91)90095-6.
33. López E, Elez M, Matic I, Blázquez J. 2007. Antibiotic-mediated recom-
bination: ciprofloxacin stimulates SOS-independent recombination of di-
vergent sequences in Escherichia coli. Mol Microbiol 64:83–93. http://dx
.doi.org/10.1111/j.1365-2958.2007.05642.x.
34. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. 1995. Risk factors for
acquisition of urinary tract infections caused by ciprofloxacin resistant
Escherichia coli. J Urol 153:117–120. http://dx.doi.org/10.1097/00005392
-199501000-00040.
35. Remer T, Manz F. 1995. Potential renal acid load of foods and its influ-
ence on urine pH. J Am Diet Assoc 95:791–797. http://dx.doi.org/10.1016
/S0002-8223(95)00219-7.
36. Remer T. 2000. Influence of diet on acid-base balance. Semin Dial
13:221–226.
37. Losito A, Nunzi EG, Covarelli C, Nunzi E, Ferrara G. 2009. Increased
acid excretion in kidney stone formers with essential hypertension. Neph-
rol Dial Transplant 24:137–141.
38. Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K.
2006. Urine composition in type 2 diabetes: predisposition to uric acid
nephrolithiasis. J Am Soc Nephrol 17:1422–1428. http://dx.doi.org/10
.1681/ASN.2005121246.
39. Berend K, de Vries APJ, Gans ROB. 2014. Physiological approach to
assessment of acid-base disturbances. N Engl J Med 371:1434 –1445. http:
//dx.doi.org/10.1056/NEJMra1003327.
40. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY.
2004. Association of urinary pH with body weight in nephrolithiasis.
Kidney Int 65:1422–1425. http://dx.doi.org/10.1111/j.1523-1755.2004
.00522.x.
41. Aparicio VA, Nebot E, García-del Moral R, Machado-Vílchez M, Porres
JM, Sánchez C, Aranda P. 2013. Dietas hiperproteicas y estado renal en
ratas. Nutr Hosp 28:232–237.
42. Ferrando SJ, Levenson JL, Owen JA (ed). 2010. Clinical manual of
psychopharmacology in the medically ill. American Psychiatric Publish-
ing, Washington, DC.
43. Kovesdy CP. 2012. Metabolic acidosis and kidney disease: does bicarbon-
ate therapy slow the progression of CKD? Nephrol Dial Transplant 27:
3056 –3062. http://dx.doi.org/10.1093/ndt/gfs291.
44. Fjellstedt E, Denneberg T, Jeppsson J-O, Tiselius H-G. 2001. A com-
parison of the effects of potassium citrate and sodium bicarbonate in the
alkalinization of urine in homozygous cystinuria. Urol Res 29:295–302.
http://dx.doi.org/10.1007/s002400100200.
45. Kamberi M, Tsutsumi K, Kotegawa T, Kawano K, Nakamura K, Niki Y,
Nakano S. 1999. Influences of urinary pH on ciprofloxacin pharmacoki-
netics in humans and antimicrobial activity in vitro versus those of spar-
floxacin. Antimicrob Agents Chemother 43:525–529.
Martín-Gutiérrez et al.
4258 aac.asm.org July 2016 Volume 60 Number 7Antimicrobial Agents and Chemotherapy
 on July 24, 2017 by U
S
E
/B
C
T
A
.G
E
N
 U
N
IV
E
R
S
IT
A
R
IA
http://aac.asm
.org/
D
ow
nloaded from
 
